» Articles » PMID: 16080706

Modulating the Actions of NK Cell-mediated Cytotoxicity Using Lipid-PEG (n) and Inhibitory Receptor-specific Antagonistic Peptide Conjugates

Overview
Journal Biotechnol Prog
Date 2005 Aug 6
PMID 16080706
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Regulating the cell surface modulates the actions of the biological cell response, derives practical applications, and is of scientific interest. On the basis of our previous study using dioleylphosphatidylethanolamine poly(ethylene glycol) with multiple units of ethyleneoxide (DOPE-PEG (n)), we demonstrated the potency of DOPE-PEG (80) as a cell surface modulator. We prepared conjugates of DOPE-PEG (80) and two antagonistic peptides (C1, SGGGCLFNLPWLCG; C26, SGGGCPFSFLPWCG), specifically designed for the inhibitory receptor of natural killer (NK) cells. We confirmed that NK cells exhibited cytotoxicity against DOPE-PEG (80)-peptides-incorporated target cells. We further investigated whether the DOPE-PEG (80)-peptides could affect the cytotoxicity of NK cells in a concentration-dependent manner. C1 peptide showed down-regulation of cytotoxicity at higher concentration, whereas C26 peptide exhibited the saturated cytotoxicity of NK cells at the same concentration. These results suggest that DOPE-PEG (80) can achieve the role of a cell surface modulator without inhibiting the action of conjugated molecules, despite their relatively small size.

Citing Articles

Chemical Reactive Anchoring Lipids with Different Performance for Cell Surface Re-engineering Application.

Vabbilisetty P, Boron M, Nie H, Ozhegov E, Sun X ACS Omega. 2018; 3(2):1589-1599.

PMID: 29503972 PMC: 5830686. DOI: 10.1021/acsomega.7b01886.


Biomolecular engineering for nanobio/bionanotechnology.

Nagamune T Nano Converg. 2017; 4(1):9.

PMID: 28491487 PMC: 5401866. DOI: 10.1186/s40580-017-0103-4.


Poly(ethylene glycol)-Lipid-Conjugated Antibodies Enhance Dendritic Cell Phagocytosis of Apoptotic Cancer Cells.

Tomita U, Yamaguchi S, Sugimoto Y, Takamori S, Nagamune T Pharmaceuticals (Basel). 2013; 5(5):405-16.

PMID: 24281554 PMC: 3763647. DOI: 10.3390/ph5050405.